# DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Source: https://onco.cc/trials/nct07544654/  
OnCo record `nct07544654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Carboplatin and Etoposide in neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.

## Summary

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy is a phase 3 interventional study registered as NCT07544654 by Boehringer Ingelheim, with 390 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-12-13. Interventions recorded: Obrixtamig, Carboplatin, Etoposide and Ventana DLL3 RxDx assay.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07544654
- Phase: 3
- Setting: A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
- Sponsor: Boehringer Ingelheim
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT07544654: https://clinicaltrials.gov/study/NCT07544654

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct07544654.json